Sparks commentary - Immix Biopharma

Healthcare

Sparks - Immix Biopharma

More on this equity
Scientist using protective robber gloves for handling substances and experiments
Immix (NASDAQ: IMMX) to present NEXICART-2 update at ASH 2025
Published by Arron Aatkar, PhD

Immix Biopharma has announced that it will present updated clinical data relating to its lead CAR-T asset, NXC-201, in relapsed/refractory amyloid light chain amyloidosis (r/r ALA) at the upcoming American Society of Hematology 2025 Annual Meeting (ASH 2025; 6–9 December). The data will come from the ongoing US-based NEXICART-2 trial, which is a multi-site, Phase I/II clinical study with a registrational design. The most recent clinical update corresponded to 10 out of the expected 40 patients, and hence, the update at ASH 2025 represents an important upcoming catalyst.

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.